A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...
Pharmaceutical Technology on MSN5d
AstraZeneca and Alteogen agree on ALT-B4 platform techAstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.
The Parainfluenza Virus Infection market is expected to surge due to the disease's increasing prevalence and awareness during ...
The biotechnology corporation Alteogen announced on the 17th that it signed a technology export contract with the global pharmaceutical company Astrazeneca's biopharmaceutical subsidiary MedImmune to ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...
The Chosun Ilbo on MSN4d
S. Korea's biotech sector kicks off 2025 with multi-billion-dollar dealsS. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...
MedPage Today on MSN5d
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op ImmunotherapyTwo neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback